TipRanks
Elevance Health (CH:A58)
:A58
Switzerland Market
A58
Elevance Health
RESEARCH TOOLSreports

Elevance Health (A58) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

A58 Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A58 Stock 12 Month Forecast

Average Price Target

―
Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is CHF371.84 with a high forecast of CHF406.49 and a low forecast of CHF327.36. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF406.49Average Price TargetCHF371.84Lowest Price TargetCHF327.36
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:A58
Andrew Mok CFA
Barclays
Barclays
CHF380.67→CHF390.67
Buy
―
Reiterated
10/07/26
Barclays Sticks to Their Buy Rating for Elevance Health (ELV)
Bernstein Analyst forecast on CH:A58
Lance Wilkes
Bernstein
Bernstein
CHF406.49
Buy
―
Reiterated
10/05/26
Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)
UBS Analyst forecast on CH:A58
A.J. Rice
UBS
UBS
CHF383.17
Buy
―
Reiterated
09/18/26
Elevance Health: Strong Medicaid Rates and Disciplined Pricing Drive Buy Rating and Earnings Confidence
Wells Fargo Analyst forecast on CH:A58
Stephen Baxter
Wells Fargo
Wells Fargo
CHF394
Buy
―
Reiterated
09/15/26
Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)
Bank of America Securities Analyst forecast on CH:A58
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
CHF383.17→CHF399.83
Buy
―
Reiterated
09/11/26
Elevance Health price target raised to $480 from $460 at BofAElevance Health price target raised to $480 from $460 at BofA
Argus Research Analyst forecast on CH:A58
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Morgan Stanley Analyst forecast on CH:A58
Erin Wright
Morgan Stanley
Morgan Stanley
CHF336.52
Hold
―
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on CH:A58
Whit Mayo
Leerink Partners
Leerink Partners
CHF303.2→CHF329.03
Hold
―
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on CH:A58
Ryan Langston
TD Cowen
TD Cowen
CHF387.33
Buy
―
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
David S Macdonald
Truist Financial
Truist Financial
CHF395.66
Buy
―
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on CH:A58
David Windley
Jefferies
Jefferies
CHF325.69→CHF374.84
Buy
―
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Robert W. Baird Analyst forecast on CH:A58
Michael Ha
Robert W. Baird
Robert W. Baird
CHF275.71→CHF327.36
Hold
―
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on CH:A58
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on CH:A58
Ben Hendrix
RBC Capital
RBC Capital
CHF365.68→CHF353.18
Hold
―
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on CH:A58
Scott Fidel
Goldman Sachs
Goldman Sachs
CHF308.2→CHF329.03
Hold
―
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:A58
Andrew Mok CFA
Barclays
Barclays
CHF380.67→CHF390.67
Buy
―
Reiterated
10/07/26
Barclays Sticks to Their Buy Rating for Elevance Health (ELV)
Bernstein Analyst forecast on CH:A58
Lance Wilkes
Bernstein
Bernstein
CHF406.49
Buy
―
Reiterated
10/05/26
Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)
UBS Analyst forecast on CH:A58
A.J. Rice
UBS
UBS
CHF383.17
Buy
―
Reiterated
09/18/26
Elevance Health: Strong Medicaid Rates and Disciplined Pricing Drive Buy Rating and Earnings Confidence
Wells Fargo Analyst forecast on CH:A58
Stephen Baxter
Wells Fargo
Wells Fargo
CHF394
Buy
―
Reiterated
09/15/26
Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)
Bank of America Securities Analyst forecast on CH:A58
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
CHF383.17→CHF399.83
Buy
―
Reiterated
09/11/26
Elevance Health price target raised to $480 from $460 at BofAElevance Health price target raised to $480 from $460 at BofA
Argus Research Analyst forecast on CH:A58
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Morgan Stanley Analyst forecast on CH:A58
Erin Wright
Morgan Stanley
Morgan Stanley
CHF336.52
Hold
―
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on CH:A58
Whit Mayo
Leerink Partners
Leerink Partners
CHF303.2→CHF329.03
Hold
―
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on CH:A58
Ryan Langston
TD Cowen
TD Cowen
CHF387.33
Buy
―
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on CH:A58
David S Macdonald
Truist Financial
Truist Financial
CHF395.66
Buy
―
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on CH:A58
David Windley
Jefferies
Jefferies
CHF325.69→CHF374.84
Buy
―
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Robert W. Baird Analyst forecast on CH:A58
Michael Ha
Robert W. Baird
Robert W. Baird
CHF275.71→CHF327.36
Hold
―
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on CH:A58
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on CH:A58
Ben Hendrix
RBC Capital
RBC Capital
CHF365.68→CHF353.18
Hold
―
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on CH:A58
Scott Fidel
Goldman Sachs
Goldman Sachs
CHF308.2→CHF329.03
Hold
―
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
MDWDMediwound
TRVITrevi Therapeutics
WSTWest Pharmaceutical Services
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
George HillDeutsche Bank
Success Rate
12/18 ratings generated profit
67%
Average Return
+3.65%
Copying George Hill's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.65% per trade.
1 Year
George HillDeutsche Bank
Success Rate
14/18 ratings generated profit
78%
Average Return
+15.42%
Copying George Hill's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +15.42% per trade.
2 Years
A.J. RiceUBS
Success Rate
26/30 ratings generated profit
87%
Average Return
+36.42%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +36.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A58 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
30
27
21
20
10
Hold
9
9
9
8
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
36
30
28
11
In the current month, A58 has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. A58 average Analyst price target in the past 3 months is 371.84.
Each month's total comprises the sum of three months' worth of ratings.

A58 Financial Forecast

A58 Earnings Forecast

Next quarter’s earnings estimate for A58 is CHF3.91 with a range of CHF3.79 to CHF4.16. The previous quarter’s EPS was CHF6.21. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s earnings estimate for A58 is CHF3.91 with a range of CHF3.79 to CHF4.16. The previous quarter’s EPS was CHF6.21. A58 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Sales Forecast

Next quarter’s sales forecast for A58 is CHF41.09B with a range of CHF39.81B to CHF42.48B. The previous quarter’s sales results were CHF42.04B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.
Next quarter’s sales forecast for A58 is CHF41.09B with a range of CHF39.81B to CHF42.48B. The previous quarter’s sales results were CHF42.04B. A58 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year A58 has Performed in-line its overall industry.

A58 Stock Forecast FAQ

What is CH:A58’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 371.84.
    What is CH:A58’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:A58, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Elevance Health a Buy, Sell or Hold?
        Elevance Health has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
          What is Elevance Health’s share price target?
          The average share price target for Elevance Health is 371.84. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF406.49 ,and the lowest forecast is CHF327.36. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Elevance Health?
            Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
              How can I buy shares of Elevance Health?
              To buy shares of CH:A58, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.